Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Plain-language summary

This is a registry study of patients with non-small cell lung cancer who developed resistance over time to small-molecule kinase inhibitors targeting EGFR, using tumor biopsies for RNA analysis to understand the causes of resistance. People with unresectable or metastatic NSCLC whose disease progressed while receiving a tyrosine kinase inhibitor could take part. This was a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Memorial Sloan Kettering Cancer Center

Intervention

Tumor core biopsy for RNA isolation

Start date

8/1/2004

Estimated completion

2/1/2016

Countries

United States

Related genes

Locations

• Basking Ridge, United States
• Commack, United States
• New York, United States
• Rockville Centre, United States
• Sleepy Hollow, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Patients diagnosed with unresectable or metastatic non-small cell lung cancer (NSCLC) and who fulfill the following eligibility criteria will be considered eligible for this study.

* Patient must have previously received treatment with small molecule kinase inhibitors targeting at least, in part, EGFR patients may have received other treatments since treatment with small molecule kinase inhibitors including radiation or chemotherapy)
* Development of disease progression while actively receiving tyrosine kinase inhibitor
* Signed informed consent

Exclusion Criteria:

* None